Candidature YC de Encepheal Therapeutics

Summer 2019Inactive

Encepheal Therapeutics a été sélectionné par Y Combinator dans le cadre du batch Summer 2019 en tant qu'entreprise Healthcare. Ci-dessous : ce que fait l'entreprise, qui l'a fondée, et sa candidature à YC, reconstruite question par question dans le vrai formulaire YC.

Batch YC: Summer 2019
Secteur d'activité: HealthcareTherapeutics
Taille de l'équipe: 3
Statut: Inactive
Lancé: 2019

Fondateurs

Aaron LazarusFounder
Omeed RahimiFounder

Ce que fait Encepheal Therapeutics

EncepHeal is developing medications to treat substance abuse. Our first product is a small molecule therapeutic for stimulants like cocaine and methamphetamine, of which there are no FDA approved treatments. Our small molecule technology are atypical inhibitors of the dopamine transporter. Cocaine itself is an inhibitor of the same transporter. Directly reducing craving or positive reinforcement is a successful treatment strategy for addiction. Methadone or buprenorphine (Suboxone) are key examples of this for opioid use disorder. However, these types of medications can be addictive themselves. This has been a major hurdle for medication development for cocaine addiction and has led to many leaders in the addiction space to abandon the dopamine transporter as a target. At EncepHeal, we believe that the dopamine transporter should not be abandoned and instead focusing on fixing the abuse liability problem. Therefore with our partners at the National Institutes of Health, we have shown that these new, allosteric modulators at the dopamine transporter do not display addictive tendencies in animal models. They are also effective at curbing cocaine addiction. Our management team has two co-founders, Omeed Rahimi and Aaron Lazarus, as well as an experienced addiction pharmacologist as their research officer. The team has an advisory board with entrepreneurial and addiction drug development experience as well as expert partners at the National Institute on Drug Abuse, a subset of the NIH, and Wake Forest. Our team has had success in raising non-dilutive funding and has expertise with SBIR/STTR grants. We are looking for help in better connecting with the biotech/pharmaceutical industry.

Candidature YC de Encepheal Therapeutics, reconstruite

Candidature Y Combinator

Encepheal Therapeutics, promotion Summer 2019. Les vraies questions de candidature, répondues à partir de données publiques.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Encepheal Therapeutics

Describe what your company does in 50 characters or less.

Medications to treat substance abuse

What is your company going to make? Please describe your product and what it does or will do.

We're developing small molecule drugs that target the dopamine transporter to treat stimulant addiction, starting with cocaine and methamphetamine. Our compounds modulate the dopamine transporter allosterically to reduce addictive cravings without the addictive properties of current dopamine transporter inhibitors.

Where do you live now, and where would the company be based after YC?

We currently live and work in Winston-Salem, NC, and the company is based there. After YC, we plan to maintain our base in Winston-Salem due to our partnerships and existing infrastructure.

Explain your decision regarding location.

We chose Winston-Salem because we have strong research collaborations with the National Institutes of Health and Wake Forest, which are local. This proximity helps us advance our drug development efficiently.

21 réponses supplémentaires dans la candidature complète

se trouvent dans la version complète. Créez un compte gratuit pour l'ouvrir dans YC Insights, à côté de tous les autres batches YC.

Voir la candidature complète

Questions fréquemment posées

Est-ce la vraie candidature YC de Encepheal Therapeutics ?

Non. Y Combinator garde les candidatures soumises privées. Ceci est une reconstruction : les vraies questions du formulaire YC, répondues à partir des données publiques de Encepheal Therapeutics (notes de lancement, parcours des fondateurs, description du produit). Cela montre comment une entreprise comme Encepheal Therapeutics se présenterait à YC, pas le texte qu'ils ont soumis.

À quel batch YC Encepheal Therapeutics appartenait-il ?

Encepheal Therapeutics faisait partie du batch Summer 2019 de Y Combinator.

Qui a fondé Encepheal Therapeutics ?

Encepheal Therapeutics a été fondé par Aaron Lazarus, Omeed Rahimi.

Que fait Encepheal Therapeutics ?

EncepHeal develops medications to treat substance abuse, starting…

Comment lire la candidature complète reconstruite ?

Créez un compte Round Funded gratuit. La version complète de la candidature de Encepheal Therapeutics en 26 réponses, et de chaque autre promotion YC, se trouve dans YC Insights.